Literature DB >> 16054416

HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2.

Isamu Mori1, Beixing Liu, Fumi Goshima, Hiroyasu Ito, Naoki Koide, Tomoaki Yoshida, Takashi Yokochi, Yoshinobu Kimura, Yukihiro Nishiyama.   

Abstract

Herpes simplex virus (HSV), a neurotropic virus, establishes life-long and, although rare, life-threatening infection in humans, and it may precipitate substantial medical and psychosocial morbidity. Here we show that HSV-1 strain HF clone 10 (HF10) exhibits impaired neuroinvasiveness in peripheral olfactory, vomeronasal and trigeminal conduits following intranasal as well as corneal inoculation. HF10 attenuation likely arises from multiple defects of HSV genes, so that HF10 will not revert to a virulent phenotype. Intranasal vaccination of mice with HF10 conferred significant protection against lethal challenge with HSV-1 and HSV-2 via the intranasal and intravaginal routes. Thus, we propose that HF10 explicitly meets the prerequisites for a candidate live attenuated HSV vaccine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054416     DOI: 10.1016/j.micinf.2005.05.007

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  7 in total

Review 1.  An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer.

Authors:  Maryum Nisar; Rehan Zafar Paracha; Sidra Adil; Sumair Naseem Qureshi; Hussnain Ahmed Janjua
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

2.  Comparative genomic sequence analysis between a standard challenge strain and a vaccine strain of duck enteritis virus in China.

Authors:  Chenghuai Yang; Qihong Li; Junping Li; Guangchuan Zhang; Huijiao Li; Yecai Xia; Hanchun Yang; Kangzhen Yu
Journal:  Virus Genes       Date:  2013-11-28       Impact factor: 2.332

Review 3.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

4.  Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant, HF10, protects mice from genital disease caused by herpes simplex virus type 2.

Authors:  Chenhong Luo; Fumi Goshima; Maki Kamakura; Yoshifumi Mutoh; Seiko Iwata; Hiroshi Kimura; Yukihiro Nishiyama
Journal:  Front Microbiol       Date:  2012-04-30       Impact factor: 5.640

5.  Trial watch: Oncolytic viruses for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-04-16       Impact factor: 8.110

6.  Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.

Authors:  Mikiya Ishihara; Naohiro Seo; Jun Mitsui; Daisuke Muraoka; Maki Tanaka; Junichi Mineno; Hiroaki Ikeda; Hiroshi Shiku
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

Review 7.  Neurogliogenesis in the mature olfactory system: a possible protective role against infection and toxic dust.

Authors:  Elena Loseva; Ti-Fei Yuan; Sergei Karnup
Journal:  Brain Res Rev       Date:  2008-11-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.